# Avantor, Inc.: overview

AVTR · NYSE · CIK 1722482 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avtr.md) · [Financials](/companies/avtr/financials.md) · [Filings](/companies/avtr/filings.md) · [Insiders](/companies/avtr/insiders.md)

Latest reported revenue: [$1.70bn](/filings/0001628280-26-067751.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 28, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-067751).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,687 d](/filings/0001628280-26-007118.md) | [1,581](/filings/0001628280-26-028141.md) | [1,683](/filings/0001628280-26-050415.md) | [1,624](/filings/0001628280-26-067751.md) | [1,664 d](/filings/0001628280-26-007118.md) | [1,581](/filings/0001628280-26-028141.md) | [1,692](/filings/0001628280-26-050415.md) | [1,698](/filings/0001628280-26-067751.md) |
| Gross margin | % | [33.4% d](/filings/0001628280-26-007118.md) | [33.8%](/filings/0001628280-26-028141.md) | [32.9%](/filings/0001628280-26-050415.md) | [32.4%](/filings/0001628280-26-067751.md) | [31.5% d](/filings/0001628280-26-007118.md) | [31.7%](/filings/0001628280-26-028141.md) | [31.7%](/filings/0001628280-26-050415.md) | [31.5%](/filings/0001628280-26-067751.md) |
| Operating margin | % | [37.8% d](/filings/0001628280-26-007118.md) | [9.3%](/filings/0001628280-26-028141.md) | [7.7%](/filings/0001628280-26-050415.md) | [(40.0%)](/filings/0001628280-26-067751.md) | [7.6% d](/filings/0001628280-26-007118.md) | [6.3%](/filings/0001628280-26-028141.md) | [7.2%](/filings/0001628280-26-050415.md) | [8.2%](/filings/0001628280-26-067751.md) |
| Net margin | % | [29.7% d](/filings/0001628280-26-007118.md) | [4.1%](/filings/0001628280-26-028141.md) | [3.8%](/filings/0001628280-26-050415.md) | [(43.8%)](/filings/0001628280-26-067751.md) | [3.1% d](/filings/0001628280-26-007118.md) | [2.7%](/filings/0001628280-26-028141.md) | [2.3%](/filings/0001628280-26-050415.md) | [12.0%](/filings/0001628280-26-067751.md) |
| Diluted EPS | $ per share | not reported | [0.09](/filings/0001628280-26-028141.md) | [0.09](/filings/0001628280-26-050415.md) | [(1.04)](/filings/0001628280-26-067751.md) | not reported | [0.06](/filings/0001628280-26-028141.md) | [0.06](/filings/0001628280-26-050415.md) | [0.30](/filings/0001628280-26-067751.md) |
| Free cash flow | $m | [146 d](/filings/0001628280-26-007118.md) | [81.3](/filings/0001628280-26-028141.md) | [125 d](/filings/0001628280-26-050415.md) | [172 d](/filings/0001628280-26-067751.md) | [117 d](/filings/0001628280-26-007118.md) | [25.2](/filings/0001628280-26-028141.md) | [141 d](/filings/0001628280-26-050415.md) | [156 d](/filings/0001628280-26-067751.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7,386](/filings/0001722482-24-000012.md) | [7,512](/filings/0001722482-25-000015.md) | [6,967](/filings/0001628280-26-007118.md) | [6,784](/filings/0001628280-26-007118.md) | [6,552](/filings/0001628280-26-007118.md) |
| Gross margin | % | [33.9%](/filings/0001722482-24-000012.md) | [34.6%](/filings/0001722482-25-000015.md) | [33.9%](/filings/0001628280-26-007118.md) | [33.6%](/filings/0001628280-26-007118.md) | [32.7%](/filings/0001628280-26-007118.md) |
| Operating margin | % | [13.2%](/filings/0001722482-24-000012.md) | [15.0%](/filings/0001722482-25-000015.md) | [10.0%](/filings/0001628280-26-007118.md) | [16.0%](/filings/0001628280-26-007118.md) | [(3.8%)](/filings/0001628280-26-007118.md) |
| Net margin | % | [7.8%](/filings/0001722482-24-000012.md) | [9.1%](/filings/0001722482-25-000015.md) | [4.6%](/filings/0001628280-26-007118.md) | [10.5%](/filings/0001628280-26-007118.md) | [(8.1%)](/filings/0001628280-26-007118.md) |
| Diluted EPS | $ per share | [0.85](/filings/0001722482-24-000012.md) | [1.01](/filings/0001722482-25-000015.md) | [0.47](/filings/0001628280-26-007118.md) | [1.04](/filings/0001628280-26-007118.md) | [(0.78)](/filings/0001628280-26-007118.md) |
| Free cash flow | $m | [843](/filings/0001722482-24-000012.md) | [710](/filings/0001722482-25-000015.md) | [724](/filings/0001628280-26-007118.md) | [692](/filings/0001628280-26-007118.md) | [495](/filings/0001628280-26-007118.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/avtr/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2020-08-21 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Sale (S) | 15,397,005 | $19.5065 | $300.3m | [Form 4](/filings/0000769993-20-000331.md) |
| 2020-07-01 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 62 | $16.99 | $1.1k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-07-01 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Sale (S) | 13,404 | $17.09 | $229.1k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-07-01 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Sale (S) | 2,006 | $16.99 | $34.1k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-07-01 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 347 | $16.99 | $5.9k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-07-01 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 436 | $16.99 | $7.4k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-07-01 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Sale (S) | 10,000 | $17.00 | $170.0k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-07-01 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 646 | $16.99 | $11.0k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-30 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 56 | $17.16 | $960.96 | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-30 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 1,103 | $17.10 | $18.9k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-30 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Sale (S) | 3,653 | $17.10 | $62.5k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-30 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 400 | $17.00 | $6.8k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-30 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 584 | $17.10 | $10.0k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-30 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Sale (S) | 400 | $17.00 | $6.8k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-30 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 1,910 | $17.10 | $32.7k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-26 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Sale (S) | 20 | $16.82 | $336.40 | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-26 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 20 | $16.82 | $336.40 | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-25 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Purchase (P) | 151 | $16.84 | $2.5k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-25 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Sale (S) | 151 | $16.84 | $2.5k | [Form 4/A](/filings/0001209191-20-058160.md) |
| 2020-06-23 | [Goldman Sachs & Co. LLC](/insiders/769993.md) | 10% owner | Sale (S) | 300 | $17.75 | $5.3k | [Form 4/A](/filings/0001209191-20-058160.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $1.19bn | 120,020,974 |  | Added +372,645 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $695.8m | 70,281,231 |  | Added +4,577,677 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $310.3m | 31,343,250 |  | Added +67,403 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $304.9m | 30,802,835 |  | Added +196,723 |
| [GREENHAVEN ASSOCIATES INC](/funds/846222.md) | 2026-06-30 | $243.9m | 24,637,310 |  | Added +2,043,472 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $213.6m | 21,572,974 |  | Added +851,895 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $202.1m | 20,412,181 |  | Added +3,517,532 |
| [Engine Capital Management, LP](/funds/1665590.md) | 2026-06-30 | $196.6m | 19,860,830 |  | Added +80,000 |
| [BARROW HANLEY MEWHINNEY & STRAUSS LLC](/funds/313028.md) | 2026-06-30 | $195.4m | 19,735,968 |  | Reduced −2,622,431 |
| [New Mountain Capital, L.L.C.](/funds/1407718.md) | 2026-06-30 | $138.6m | 14,000,000 |  | Unchanged |

## Recent filings

[All 765 filings](/companies/avtr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 09:03 ET | [10-Q](/filings/0001628280-26-067751.md) | Quarterly report, period 2026-09-30 | 0001628280-26-067751 |
| 2026-10-28 | 06:08 ET | [8-K](/filings/0001628280-26-067710.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-067710 |
| 2026-09-21 | 07:14 ET | [8-K](/filings/0000947871-26-000877.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000947871-26-000877 |
| 2026-09-21 | 07:08 ET | [8-K](/filings/0000947871-26-000876.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000947871-26-000876 |
| 2026-08-27 | 16:40 ET | [8-K/A](/filings/0001628280-26-059273.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-059273 |
| 2026-07-29 | 09:01 ET | [10-Q](/filings/0001628280-26-050415.md) | Quarterly report, period 2026-06-30 | 0001628280-26-050415 |
| 2026-07-29 | 06:13 ET | [8-K](/filings/0001628280-26-050333.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-050333 |
| 2026-07-17 | 16:44 ET | [8-K](/filings/0001628280-26-048676.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001628280-26-048676 |
| 2026-05-12 | 16:32 ET | [8-K](/filings/0001628280-26-034146.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001628280-26-034146 |
| 2026-04-29 | 09:02 ET | [10-Q](/filings/0001628280-26-028141.md) | Quarterly report, period 2026-03-31 | 0001628280-26-028141 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-007118.md), filed Feb 11, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1722482
- Tickers: AVTR
- Exchange: NYSE
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 09:10 ET. No prices; not investment advice.